Sickle Cell Disease Treatment Market Size is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock detailed insights into the Sickle Cell Disease Market by downloading the comprehensive report from DelveInsight @ Sickle Cell Disease Treatment Market Size- https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Sickle Cell Disease Market Report
• On January 08, 2026- Hillhurst Biopharmaceuticals Inc. announced a Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.
• On January 05, 2026- Bristol-Myers Squibb conducted a study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
• In 2023, the total market size of Sickle Cell Disease was approximately USD 650 million, which is expected to increase by 2034 during the study period (2020-2034) in the 6MM.
• Among the 6MM, the United States accounted for the highest market share in 2023 accounting for ~USD 603 million, followed by France, and the UK for Sickle Cell Disease.
• During the forecast period (2024-2034), pipeline candidates such as Etavopivat, Inclacumab (PF-07940370), Reni-cel (EDIT-301) and Osivelotor (GBT-601) are expected to be the major contributors for driving the rise in Sickle Cell Disease market size.
• Among the emerging therapies, Casgevy (Exa-cel) is expected to garner the largest market share by 2034 in the 6MM.
• Gene therapies come up with many challenges, such as market access and reimbursements, and target a niche pool hence having a lower market share.
• The leading Sickle Cell Disease Companies such as Pfizer, Agios Pharmaceuticals, Fulcrum Therapeutics, Novo Nordisk, Scribe Therapeutics, Sanofi, and others.
• Promising Sickle Cell Disease Therapies such as Osivelotor (GBT-601), Mitapivat, Pociredir, Inclacumab, Etavopivat, CRISPR by Design, and others.

Gain a competitive edge in the Sickle Cell Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Sickle Cell Disease Treatment Drugs- https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sickle Cell Disease Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Sickle Cell Disease
• Total Diagnosed Prevalent Cases of Sickle Cell Disease
• Type‐specific Cases of Sickle Cell Disease
• Treated Cases of Sickle Cell Disease

Discover the latest breakthroughs in the Sickle Cell Disease Market Report-Download the full report now! @ Sickle Cell Disease Prevalence- https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sickle Cell Disease Marketed Therapies
CASGEVY (exagamglogene autotemcel): Vertex Pharmaceuticals/CRISPR Therapeutics
CASGEVY is a genome-edited cellular therapy consisting of autologous CD34+ hematopoietic stem cells (HSCs) edited by CRISPR/Cas9 technology at the erythroid-specific enhancer region of the BCL11A gene. CASGEVY is intended for one-time administration via a hematopoietic stem cell transplant procedure where the patient's own CD34+ cells are modified to reduce BCL11A expression in erythroid lineage cells, leading to increased fetal hemoglobin (HbF) production. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate vaso-occlusive crises for patients with Sickle Cell Disease. CASGEVY was later granted conditional marketing authorization in Great Britain by the UK. Medicines and Healthcare Products Regulatory Agency and by the National Health Regulatory Authority in Bahrain for patients 12 years of age and older with Sickle Cell Disease characterized by recurrent vaso-occlusive crises or transfusion-dependent beta-thalassemia (TDT), for whom hematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related hematopoietic stem cell donor is not available.

ENDARI (L-glutamine): Emmaus Life Sciences
ENDARI (L-glutamine) is an oral-administered pharmaceutical grade L-glutamine (PGLG), an amino acid formulation to relieve pain, swelling, and other complications of sickle cell anemia in adults and children 5 years and older. ENDARI reduces oxidant damage to red blood cells by improving the redox potential of nicotinamide adenine dinucleotide (NAD), a coenzyme identified as the primary regulator of oxidation. ENDARI received Orphan Drug designation (ODD) in the US, Orphan Medicinal Product designation in the EU, and Fast Track designation (FTD) from the FDA. In July 2017, the FDA approved ENDARI (L-glutamine oral powder) to reduce the severe complications of sickle cell disease in adult and pediatric patients aged 5 and older.

Emerging Sickle Cell Disease Drugs Profile
Mitapivat: Agios Pharmaceuticals
Mitapivat is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. It has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruvate kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate. In February 2022, the FDA approved PYRUKYND (mitapivat) to treat hemolytic anemia in adults with pyruvate kinase deficiency. The company has initiated a Phase II/III trial to evaluate mitapivat in sickle cell patients.

Inclacumab: Pfizer
Inclacumab is a novel, fully human monoclonal antibody that selectively targets P-selectin. This protein mediates cell adhesion and is clinically validated to reduce pain due to VOCs in people with Sickle Cell Disease. Preclinical results suggest that inclacumab can be a best-in-class option for reducing VOCs in people with Sickle Cell Disease, with the potential for quarterly rather than monthly dosing. The company has completed one Phase II study, and it is currently in the Phase III stage of clinical development for the treatment of Sickle cell disease.

Sickle Cell Disease Market Outlook
An effective cure for a disease is the utmost requirement in Sickle Cell Disease patients. Current therapies only provide symptomatic treatment such as relief in pain crises, inflammation, reduction in the frequency of vaso-occlusive crisis, improved oxygen supply, etc., enhancing quality of life. Recurring blood transfusion and cell therapies also sustain symptom management in Sickle Cell Disease patients. Sickle Cell Disease is the reality of many people across the US. Yet, patients often experience poor care, especially from non-specialist healthcare providers who may lack the training to provide good, comprehensive care. It shows the scarcity of healthcare infrastructure to provide holistic treatment, which fuels unsatisfactory symptom management.

Discover key developments and opportunities in the Sickle Cell Disease Market. Click here to learn more from DelveInsight's latest report @ Sickle Cell Disease Therapeutics Market Size- https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sickle Cell Disease Therapeutics Market
Sickle Cell Disease (Sickle Cell Disease) is a group of lifelong inherited conditions that affect hemoglobin. It is characterized as a chronic hemolytic disorder marked by the tendency of hemoglobin molecules within red blood cells to polymerize and deform the red cell into sickle (or crescent) shape (Hb S), resulting in characteristic vaso-occlusive events and accelerated hemolysis. Sickle Cell Disease is classified as a large-vessel vasculitis but also involves medium and small arteritis; sickle cell disease is inherited in an autosomal fashion, whether in the homozygous or double heterogeneous state. Sickle cell disease is called sickle cell anemia (SCA) when there is an inheritance in the homozygous state. Other known Sickle Cell Disease genotypes include hemoglobin SC disease, sickle beta plus thalassemia, sickle beta zero thalassemia (which has similar severity with sickle cell anemia), hemoglobin SD Punjab disease, hemoglobin SO Arab disease, and others. Hemoglobin S (Hb S) differs from normal hemoglobin (Hb A) because of the substitution of valine for glutamic acid in the sixth position in the ß-globin gene.

Sickle Cell Disease Treatment Market
The Sickle Cell Disease treatment goals aims to relieve pain, prevent infections, and specifically manage complications. Sickle Cell Disease treatment can be divided into First line treatment and second line treatment. The first line treatment includes management of pain, vaso-occlusive crisis, and chronic symptoms by using various medications, Second line treatment includes gene therapy and bone marrow transplantation. Patients with Sickle Cell Disease use medications to make their disease less severe and treat symptoms. FDA approved medications include Voxelotor, Crizanlizumab, Hydroxyurea, L-glutamine, and others. Moreover, NSAIDS, Opioids, Iron chelating agents, Antibiotics, Folic acid and others are used for the pain and other complications associated with Sickle Cell Disease.

Download DelveInsight's Sickle Cell Disease Market report today and stay ahead in this rapidly evolving field. @ Sickle Cell Disease Ongoing Clinical Trials- https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Sickle Cell Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Sickle Cell Disease Companies- Pfizer, Agios Pharmaceuticals, Fulcrum Therapeutics, Novo Nordisk, Scribe Therapeutics, Sanofi, and others.
• Sickle Cell Disease Therapies- Osivelotor (GBT-601), Mitapivat, Pociredir, Inclacumab, Etavopivat, CRISPR by Design, and others.
• Sickle Cell Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Sickle Cell Disease Unmet Needs, KOL's views, Analyst's views, Sickle Cell Disease Market Access and Reimbursement

Download the report to understand which factors are driving Sickle Cell Disease Market Trends @ Sickle Cell Disease Market Trends- https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Sickle Cell Disease Market Report Introduction
2. Executive Summary for Sickle Cell Disease
3. SWOT analysis of Sickle Cell Disease
4. Sickle Cell Disease Patient Share (%) Overview at a Glance
5. Sickle Cell Disease Market Overview at a Glance
6. Sickle Cell Disease Background and Overview
7. Sickle Cell Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Sickle Cell Disease
9. Sickle Cell Disease Current Treatment and Medical Practices
10. Sickle Cell Disease Unmet Needs
11. Sickle Cell Disease Emerging Therapies
12. Sickle Cell Disease Market Outlook
13. Country-Wise Sickle Cell Disease Market Analysis
14. Sickle Cell Disease Market Access and Reimbursement of Therapies
15. Sickle Cell Disease Market Drivers
16. Sickle Cell Disease Market Barriers
17. Sickle Cell Disease Appendix
18. Sickle Cell Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.